RZLT
Rezolute, Inc.
Biotechnology · Healthcare · United States
3.95
close · 2026-10-30
value
52
cheaper than peers52
quality
55
stronger fundamentals55
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 2 years ago | -25.6% | 59 |
| cash flow yield, 2 years ago | -11.7% | 56 |
| cash flow yield, 3 years ago | -10.4% | 54 |
| earnings yield, latest year | -24.8% | 53 |
| cash flow yield, 1 year ago | -15.0% | 53 |
| cash flow yield, latest year | -18.1% | 50 |
| earnings yield, 1 year ago | -33.7% | 48 |
| earnings yield, 3 years ago | -58.7% | 48 |
| price to book | 3.78× | 36 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 1.0% | 73 |
| operating margin | 0.0% | 50 |
| return on equity | -81.7% | 36 |
3 of 4 measures available
Facts
| market cap | $382M |
| free cash flow | -$43.7M |
| employees | 68 |
| first trade | 2013-01-14 |
| next earnings | 2026-09-24 |
| fundamentals updated | 2026-09-24 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.98 | -1.33 | -1.01 | -2.32 |
| free cash flow | -$69.1M | -$57.4M | -$44.6M | -$39.6M |
| net income | -$74.4M | -$68.5M | -$51.8M | -$41.1M |
| revenue | $0 | $0 | $0 | $0 |
| unusual items | not reported | -$2.9M | -$5,000 | $2.3M |